Medrexcare Pharma Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
- Paid Up Capital ₹ 0.10 M
- Company Age 12 Year, 4 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 5.30 M
- Revenue Growth -9.02%
- Profit Growth -14.21%
- Ebitda -8.74%
- Net Worth 14.59%
- Total Assets 6.58%
About Medrexcare Pharma
Medrexcare Pharma Private Limited (MPPL) is a Private Limited Indian Non-Government Company incorporated in India on 28 September 2012 and has a history of 12 years and four months. Its registered office is in Hyderabad, Telangana, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M.
The company currently has active open charges totaling ₹5.30 M.
Anitha Puritipati and Bantroth Reddy serve as directors at the Company.
Company Details
- Location
Hyderabad, Telangana, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U24232TG2012PTC083331
- Company No.
083331
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
28 Sep 2012
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Hyderabad
Industry
What products or services does Medrexcare Pharma Private Limited offer?
Medrexcare Pharma Private Limited offers a wide range of products and services, including Popular Category, Bone & Joint Care.
Who are the key members and board of directors at Medrexcare Pharma?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Anitha Puritipati  | Director | 28-Sep-2012 | Current |
| Bantroth Reddy | Director | 28-Sep-2012 | Current |
Financial Performance of Medrexcare Pharma.
Medrexcare Pharma Private Limited, for the financial year ended 2023, experienced Minor drop in revenue, with a 9.02% decrease. The company also saw a substantial fall in profitability, with a 14.21% decrease in profit. The company's net worth Soared by an impressive increase of 14.59%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Medrexcare Pharma?
In 2023, Medrexcare Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
₹5.30 M
₹0
Charges Breakdown by Lending Institutions
- Others : 0.53 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 10 May 2023 | Others | ₹5.30 M | Open |
How Many Employees Work at Medrexcare Pharma?
Medrexcare Pharma has a workforce of 16 employees as of Apr 01, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Medrexcare Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Medrexcare Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.